879 related articles for article (PubMed ID: 33741992)
21. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J
Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821
[TBL] [Abstract][Full Text] [Related]
22. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
[TBL] [Abstract][Full Text] [Related]
23. Prospects for a MERS-CoV spike vaccine.
Zhou Y; Jiang S; Du L
Expert Rev Vaccines; 2018 Aug; 17(8):677-686. PubMed ID: 30058403
[TBL] [Abstract][Full Text] [Related]
24. Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.
Lee HJ; Park N; Cho HJ; Yoon JK; Van ND; Oh YK; Kim YB
Vaccine; 2010 Feb; 28(6):1613-9. PubMed ID: 19961961
[TBL] [Abstract][Full Text] [Related]
25. Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions.
Lee C; Kim M; Chun J; Kim S; Yoon D; Lee H; Bang H; Lee HJ; Park H; Kim YB
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543967
[TBL] [Abstract][Full Text] [Related]
26. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
27. Receptor-binding domain-based subunit vaccines against MERS-CoV.
Zhang N; Tang J; Lu L; Jiang S; Du L
Virus Res; 2015 Apr; 202():151-9. PubMed ID: 25445336
[TBL] [Abstract][Full Text] [Related]
28. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans.
Yu S; Chen K; Fang L; Mao H; Lou X; Li C; Zhang Y
Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34199384
[TBL] [Abstract][Full Text] [Related]
29. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
[TBL] [Abstract][Full Text] [Related]
30. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice.
Wang C; Zheng X; Gai W; Wong G; Wang H; Jin H; Feng N; Zhao Y; Zhang W; Li N; Zhao G; Li J; Yan J; Gao Y; Hu G; Yang S; Xia X
Antiviral Res; 2017 Apr; 140():55-61. PubMed ID: 28040513
[TBL] [Abstract][Full Text] [Related]
31. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of candidate vaccine approaches for MERS-CoV.
Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
[TBL] [Abstract][Full Text] [Related]
33. Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.
Chao CW; Sprouse KR; Miranda MC; Catanzaro NJ; Hubbard ML; Addetia A; Stewart C; Brown JT; Dosey A; Valdez A; Ravichandran R; Hendricks GG; Ahlrichs M; Dobbins C; Hand A; Treichel C; Willoughby I; Walls AC; McGuire AT; Leaf EM; Baric RS; Schäfer A; Veesler D; King NP
bioRxiv; 2024 Mar; ():. PubMed ID: 38558973
[TBL] [Abstract][Full Text] [Related]
34. Receptor-binding domain as a target for developing SARS vaccines.
Zhu X; Liu Q; Du L; Lu L; Jiang S
J Thorac Dis; 2013 Aug; 5 Suppl 2(Suppl 2):S142-8. PubMed ID: 23977435
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein.
Ozharovskaia TA; Zubkova OV; Dolzhikova IV; Gromova AS; Grousova DM; Tukhvatulin AI; Popova O; Shcheblyakov DV; Scherbinin DN; Dzharullaeva AS; Erokhova AS; Shmarov MM; Loginova SY; Borisevich SV; Naroditsky BS; Logunov DY; Gintsburg AL
Acta Naturae; 2019; 11(1):38-47. PubMed ID: 31024747
[TBL] [Abstract][Full Text] [Related]
36. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
[TBL] [Abstract][Full Text] [Related]
37. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
[TBL] [Abstract][Full Text] [Related]
38. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
39. Conjugation of Human β-Defensin 2 to Spike Protein Receptor-Binding Domain Induces Antigen-Specific Protective Immunity against Middle East Respiratory Syndrome Coronavirus Infection in Human Dipeptidyl Peptidase 4 Transgenic Mice.
Kim J; Yang YL; Jeong Y; Jang YS
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33139653
[TBL] [Abstract][Full Text] [Related]
40. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
Wang W; Wang H; Deng Y; Song T; Lan J; Wu G; Ke C; Tan W
Emerg Microbes Infect; 2016 Nov; 5(11):e113. PubMed ID: 27826140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
